Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Therapies inhibiting receptor tyrosine kinases (RTKs) are effective against some human cancers when they lead to simultaneous downregulation of PI3K/AKT and MEK/ERK signaling. However, mutant KRAS has the capacity to directly activate ERK and PI3K signaling, and this is thought to underlie the resistance of KRAS mutant cancers to RTK inhibitors. Here, we have elucidated the molecular regulation of both the PI3K/AKT and MEK/ERK signaling pathways in KRAS mutant colorectal cancer cells and identified combination therapies that lead to robust cancer cell apoptosis. KRAS knockdown using shRNA suppressed ERK signaling in all of the human KRAS mutant colorectal cancer cell lines examined. However, no decrease, and actually a modest increase, in AKT phosphorylation was often seen. By performing PI3K immunoprecipitations, we determined that RTKs, often IGF-IR, regulated PI3K signaling in the KRAS mutant cell lines. This conclusion was also supported by the observation that specific RTK inhibition led to marked suppression of PI3K signaling and biochemical assessment of patient specimens. Interestingly, combination of RTK and MEK inhibitors led to concomitant inhibition of PI3K and MEK signaling, marked growth suppression, and robust apoptosis of human KRAS mutant colorectal cancer cell lines in vitro and upon xenografting in mice. These findings provide a framework for utilizing RTK inhibitors in the treatment of KRAS mutant colorectal cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The IGF1R/ERBB2/3 signaling pathway may respond to the suppressed ERK and AKT signaling after KRAS (G12C) inhibitor treatment and favor the change to epithelial cell types (Fig. 5).”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [132]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our screens identified previously described MEKi sensitizers, including those that function through the PI3K/AKT/mTOR pathway (AKT1, AKT2, RICTOR, MTOR, and IGF1R), through suppression of ERK pathway feedback reactivation (or incomplete pathway inhibition) (BRAF, RAF1, MAPK1, MAPK3, KRAS, and FGFR1), and through the YAP1 pathway”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Ebi et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which is consistent with prior studies suggesting that PI3K is not universally tied to RAS activity (15,29).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“the combined inhibition of MEK and the PI3K/AKT/mTOR pathway has been widely described”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Ebi et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“High basal ERBB2/3 associated with epithelial gene signatures was observed in KRAS (G12C) cell lines and human lung cancers.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [132]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationAnaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Research works printed but not linked: 2
- Yakes, 2002, Cancer Res., 62, 4132
- Guix, 2008, J Clin Invest., 118, 2609
Cited by
Items 101–200 of 215
Hou, Z., Li, S., Xu, F., Hu, F., Lan, J., Song, D., Feng, Y., Wang, J., Luo, X., Hu, J., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.029 · Cited by 37
Gaur, S., Chen, L., Ann, V., Lin, W., Wang, Y., Chang, V. H. S., Hsu, N. Y., Shia, H.-S., & Yen, Y. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-21 · Cited by 38
Hata, A. N., Rowley, S., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Ji, F., Jung, J., Light, M., Lee, J. S., Debussche, L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.258 · Cited by 34
Self-citationCeritinib Enhances the Efficacy of Trametinib in BRAF/NRAS -Wild-Type Melanoma Cell Lines
Verduzco, D., Kuenzi, B. M., Kinose, F., Sondak, V. K., Eroglu, Z., Rix, U., & Smalley, K. S. M. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0196 · Cited by 34
Sheffels, E., Sealover, N. E., Theard, P. L., & Kortum, R. L. (2019) · Small GTPases · doi:10.1080/21541248.2019.1611168 · Cited by 31
Choi, C.-W., Kwon, J., Lim, S., & Helfman, D. M. (2016) · Oncotarget · doi:10.18632/oncotarget.11525 · Cited by 34
mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer
Mashima, T., Taneda, Y., Jang, M.-K., Mizutani, A., Muramatsu, Y., Yoshida, H., Sato, A., Tanaka, N., Sugimoto, Y., & Seimiya, H. (2017) · Oncotarget · doi:10.18632/oncotarget.18146 · Cited by 31
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
Shieh, A., Ward, A. F., Donlan, K. L., Harding-Theobald, E. R., Xu, J., Mullighan, C. G., Zhang, C., Chen, S.-C., Su, X., Downing, J. R., et al. (2013) · Blood · doi:10.1182/blood-2012-05-432252 · Cited by 28
Georgiou, A., Stewart, A., Cunningham, D., Banerji, U., & Whittaker, S. R. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1201 · Cited by 32
Agy, F. E., Bardai, S. E., Otmani, I. E., Benbrahim, Z., Karim, I. M. H., Mazaz, K., Benjelloun, E. B., Ousadden, A., Abkari, M. E., Ibrahimi, S. A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248522 · Cited by 29
Emerging Therapeutic Agents for Colorectal Cancer
Nalli, M., Puxeddu, M., Regina, G. L., Gianni, S., & Silvestri, R. (2021) · Molecules · doi:10.3390/molecules26247463 · Cited by 29
Huang, F., Han, C. L., Greer, A. L., Hillerman, S. M., Reeves, K. A., Hurlburt, W. W., Cogswell, J. P., Patel, D., Qi, Z., Fairchild, C. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0794-t · Cited by 33
Iizuka-Ohashi, M., Watanabe, M., Sukeno, M., Morita, M., Hoang, N. T. H., Kuchimaru, T., Kizaka‐Kondoh, S., Sowa, Y., Sakaguchi, K., Taguchi, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24696 · Cited by 30
Network rewiring, adaptive resistance and combating strategies in breast cancer
Cremers, C. G., & Nguyen, L. K. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.60 · Cited by 38
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Adachi, Y., Kimura, R., Hirade, K., & Ebi, H. (2021) · Cancers · doi:10.3390/cancers13205081 · Cited by 30
Self-citationFeng, W., Liu, Y., Bellail, A. C., Olson, J. J., Sun, S. Y., Lu, G., Ding, L., Yuan, C., Wang, G., & Hao, C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.005 · Cited by 29
Appleman, V. A., Ahronian, L. G., Cai, J., Klimstra, D. S., & Lewis, B. C. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0340-t · Cited by 32
Whitehead, C. E., Ziemke, E. K., Frankowski-McGregor, C. L., Mumby, R. A., Chung, J., Li, J., Osher, N., Coker, O., Baladandayuthapani, V., Kopetz, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00781-6 · Cited by 33
Jin, D.-J., Fang, Y., Li, Z., Chen, Z., & Xiang, J. (2014) · Oncology Reports · doi:10.3892/or.2014.3638 · Cited by 31
Self-citationYu, M., & Grady, W. M. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12448456 · Cited by 26
Inhibiting the RAS–PI3K Pathway in Cancer Therapy
Sheridan, C., & Downward, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00005-6 · Cited by 28
Climbing RAS, the Everest of Oncogenes
Russo, M., Nicolantonio, F. D., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0906 · Cited by 27
Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma
Guo, S., Hector, L.-M., Fan, K. C., Choy, E., Cote, G. M., Harmon, D. C., Nielsen, G. P., Cao, Y., Zhang, C., Mankin, H. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093996 · Cited by 25
Optical measurement of receptor tyrosine kinase oligomerization on live cells
Chung, I. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.03.026 · Cited by 25
The Role of Phosphoinositide 3-Kinase Signaling in Intestinal Inflammation
Cahill, C. M., Rogers, J. T., & Walker, W. A. (2012) · Journal of Signal Transduction · doi:10.1155/2012/358476 · Cited by 24
Advances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 25
Lee, H., Son, E., Lee, K., Lee, Y., Kim, Y., Lee, J.-C., Lim, Y., Hur, M., Kim, D., & Nam, D.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235894 · Cited by 22
“Although KRAS can directly activate PI3K signaling by binding to th p110-PI3K subunit, there s increasing evidence that PI3K activation, following ME inhibition, is correlated with RTK activity, providing the foundation for the use of RT inhibi ors in KRAS-mutant CRC [36].”
BackgroundInfluentialResistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer
Adachi, Y., Watanabe, K., Kita, K., Kitai, H., Kotani, H., Sato, Y., Inase, N., Yano, S., & Ebi, H. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx091 · Cited by 26
Self-citationLee, J., Jain, A., Kim, P., Lee, T., Kuller, A., Princen, F., In-Gu, Kim, S. H., Park, J. O., Park, Y. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103551 · Cited by 23
Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer
Fan, Y., Ding, H., Kim, D., Bach, D., Hong, J., Xu, Y., & Lee, S. K. (2019) · Cancers · doi:10.3390/cancers11050627 · Cited by 21
Yao, Y., Feng, L., Wang, Z., Chen, H., & Tan, N. (2019) · Biomaterials Science · doi:10.1039/c9bm00905a · Cited by 21
Dehner, C. A., Armstrong, A. E., Yohe, M. E., Shern, J. F., & Hirbe, A. C. (2021) · Genes · doi:10.3390/genes12101500 · Cited by 21
Role of Runx2 in Crosstalk Between Mek/Erk and PI3K/Akt Signaling in MCF‐10A Cells
Tandon, M., Chen, Z., & Pratap, J. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24939 · Cited by 21
Self-citationWeisberg, E., Nonami, A., Chen, Z., Nelson, E. A., Chen, Y., Liu, F., Cho, H., Zhang, J., Sattler, M., Mitsiades, C. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0902 · Cited by 20
Self-citationYip, W. K., Choo, C. W., Leong, V. C., Leong, P. P., Jabar, M. F., & Seow, H. F. (2013) · Apmis · doi:10.1111/apm.12152 · Cited by 22
PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK
Lu, T., Zou, Y., Xu, G., Potter, J. A., Taylor, G. L., Duan, Q., Yang, Q., Xiong, H., Qiu, H., Ye, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12940 · Cited by 22
Song, Q., Sun, X., Guo, H., & Yu, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.14009 · Cited by 18
Ebi, H., Faber, A. C., Engelman, J. A., & Yano, S. (2014) · Cancer Science · doi:10.1111/cas.12383 · Cited by 18
Self-citationConquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 23
Li, Y., Yuan, Y., Zhang, F., Guo, A., Cao, F., Song, M., Fu, Y., Xu, X., Shen, H., Zheng, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739501 · Cited by 29
Saisana, M., Griffin, S. M., & May, F. E. B. (2016) · Oncotarget · doi:10.18632/oncotarget.10642 · Cited by 17
KRAS inhibition in metastatic colorectal cancer: An update
Nusrat, M., & Yaeger, R. D. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102343 · Cited by 20
KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents
Ischenko, I., Zhi, J., Hayman, M. J., & Petrenko, O. (2017) · Oncotarget · doi:10.18632/oncotarget.14929 · Cited by 22
Smalley, I., Fang, B., Munko, A., Gibney, G. T., Koomen, J. M., & Smalley, K. S. M. (2014) · PROTEOMICS · doi:10.1002/pmic.201400200 · Cited by 16
KRAS insertion mutations are oncogenic and exhibit distinct functional properties
White, Y. N., Bagchi, A., Ziffle, J. V., Sheth, A. I., Bollag, G. E., Zhang, C., Carias, H., Dickens, D. S., Loh, M. L., Shannon, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10647 · Cited by 16
Niederst, M. J., & Benes, C. H. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1030 · Cited by 16
Self-citationYoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02727-2 · Cited by 15
PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate
Chessa, T. A. M., Jung, P., Anwar, A., Suire, S., Anderson, K. E., Barneda, D., Kielkowska, A., Sadiq, B. A., Lai, I. W., Felisbino, S. L., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.07.015 · Cited by 15
Wang, Z., Kang, B., Gao, Q., Huang, L., Di, J., Fan, Y., Yu, J., Jiang, B., Gao, F., Wang, D., et al. (2021) · Cancer Science · doi:10.1111/cas.15049 · Cited by 15
Kitazawa, M., Miyagawa, Y., Koyama, M., Nakamura, S., Hondo, N., Miyazaki, S., Muranaka, F., Tokumaru, S., Yamamoto, Y., Ehara, T., et al. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2310 · Cited by 19
Yellen, P., & Foster, D. A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.027 · Cited by 17
Baszanowska, W., Misiura, M., Ościłowska, I., Palka, J. A., & Miltyk, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020942 · Cited by 15
Stevenson, M. E., Algarzae, N. K., & Moussa, C. (2024) · Frontiers in Dementia · doi:10.3389/frdem.2024.1458038 · Cited by 15
Landras, A., de Moura, C. R., Villoutreix, B. O., Battistella, M., Sadoux, A., Dumaz, N., Ménashi, S., Fernández‐Recio, J., Lebbé, C., & Mourah, S. (2022) · Oncogene · doi:10.1038/s41388-022-02244-7 · Cited by 13
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma
Robinson, J. P., Rebecca, V. W., Kircher, D. A., Silvis, M. R., Smalley, I., Gibney, G. T., Lastwika, K. J., Chen, G., Davies, M. A., Grossman, D., et al. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000403 · Cited by 12
Pairawan, S. S., Akçakanat, A., Kopetz, S., Tapia, C., Zheng, X., Chen, H., Ha, M. J., Rizvi, Y. Q., Holla, V. R., Wang, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05193-z · Cited by 13
Change or die: Targeting adaptive signaling to kinase inhibition in cancer cells
Rebecca, V. W., & Smalley, K. S. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.031 · Cited by 12
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib
Gamba, S., Čamaj, P., Heinemann, V., Laubender, R. P., Wang, Y., Zhao, Y., Stintzing, S., Giessen, C. A., Boeck, S. H., Haertl, C., et al. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000196 · Cited by 11
Melatonin as a potential inhibitor of colorectal cancer: Molecular mechanisms
Shafabakhsh, R., Reiter, R. J., Davoodabadi, A., & Asemi, Z. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28833 · Cited by 10
Haagensen, E. J., Thomas, H. D., Schmalix, W. A., Payne, A. C., Kevorkian, L., Allen, R. A., Bevan, P., Maxwell, R. J., & Newell, D. R. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3186-4 · Cited by 11
Zhang, C., Zhang, C., Wang, K., & Wang, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04338-6 · Cited by 9
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers
Bon, G., Loria, R., Amoreo, C. A., Verdina, A., Sperduti, I., Mastrofrancesco, A., Soddu, S., Diodoro, M. G., Mottolese, M., Todaro, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11400 · Cited by 9
Li, C., Zhou, Z., Long, X., Pan, Y., Wang, R., Chen, X., & Zhao, X. (2022) · BioMed Research International · doi:10.1155/2022/6770135 · Cited by 7
Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer
Nakhchi, B. G., Kosuru, R., & Chrzanowska‐Wodnicka, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189853 · Cited by 10
Osumi, H., Muroi, A., Sakahara, M., Kawachi, H., Okamoto, T., Natsume, Y., Yamanaka, H., Takano, H., Kusama, D., Shinozaki, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74530-x · Cited by 6
Killing Tumors by Keeping Ras and PI3′ Kinase Apart
Yuan, T. L., & McCormick, F. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.015 · Cited by 5
“In K-Ras mutant human colorectal (Ebi et al., 2011) and lung (Molina-Arcas et al., 2013) cancer cell lines, IGF-1R was predominantly responsible for PI3K activation through binding to IRS adaptor proteins, with K-Ras making a relatively minor contribution.”
BackgroundFrom PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer
Voutsadakis, I. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00815-4 · Cited by 6
Raufi, A. G., Wong, W., Chen, K., Iuga, A. C., Ahmed, F. S., & Manji, G. A. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00134 · Cited by 4
BRAF Overexpression Induces Rampant Glioma Proliferation Independent of Phospho-EGFR Expression
Li, M., Wei, M., Jiang, Z., Wei, H., Lu, W., Dou, W., & Shen, L. (2014) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/37332 · Cited by 5
Patient-Derived Xenografts as Cancer Models for Preclinical Drug Screening
Williams, J. A. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_10 · Cited by 3
Song, K. W., Ong, C. C., Lin, E., Lau, J., Sodir, N. M., Jin, D. X., Hutchinson, K. E., Xie, S., Tan, J., Liang, Y., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0995 · Cited by 3
EGFR inhibition generates drug-tolerant persister cells by blocking AKT activity
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1045 · Cited by 4
Wang, M., Yu, K., Fu, W., & Yang, L. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150262 · Cited by 2
Resistance of Colorectal Tumors to Anti-EGFR Antibodies
Trusolino, L., & Leto, S. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_1 · Cited by 2
RAS signaling in lung adenocarcinoma is defined by lineage context and DUSP4 loss
Kim, M., Lamlertthon, W., Jo, H., Cui, Y., Yeon, M., Choi, H. Y., Hoadley, K. A., Smeltzer, M. P., Hayward, M. C., Wilkerson, M. D., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.200912 · Cited by 1
Zhao, M., Wang, J., Xie, J. Y., Chen, P., Zeng, Z. K., Zheng, W. F., Dang, H., Liu, J., Hou, P., & Meng, D. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112772 · Cited by 1
Mutational Activation of KRAS and BRAF in Colorectal Cancer
Pedone, K. H., Sells, J. L., & Der, C. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8412-7_5 · Cited by 1
Using Systems Pharmacology to Advance Oncology Drug Development
Kirouac, D. C. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-44534-2_19 · Cited by 2
Molecular Markers and Mutational Analysis
Clarke, C. N., & Kopetz, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-16384-0_19 · Cited by 1
On the Diophantine Equation 3 x + b3 y = 6 z
Sándor, J. (2001) · Octogon Mathematical Magazine archive · Cited by 1
Rasool, M., Haque, A., Alharthi, M. A., Sibiany, A., Alamri, M. S., Alqarni, S. M. H., Rather, I. A., Chaudhary, A., Pushparaj, P. N., & Karim, S. (2024) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2024.103477 · Cited by 1
HMMR is a novel prognostic marker and a potential therapeutic target for colon cancer
Fang, L., Lin, J., Huang, D., Li, J., Cui, W., Deng, M., & Zhang, Y. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112249 · Cited by 1
Parker, K., Ghorbanpoor, S., Malik, W., Highfield, L., Wang, J., Hensley, E., Kelley, G., Clark, S., Ranieri, M., Sahu, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.27.718135 · Cited by 1
Self-citationUsing GEMMs to investigate novel therapeutic strategies for colorectal cancer
Raja, M. (2013) · ORCA Online Research @Cardiff (Cardiff University)
Schrock, A. B. (2013) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Zuckerman, J. E. (2012) · CaltechTHESIS (California Institute of Technology) · doi:10.7907/p4ff-nq42
A moving target: challenges in treating BRAF -mutant colorectal cancer
Scott, A. J., Leong, S., Messersmith, W. A., & Lieu, C. H. (2013) · Colorectal Cancer · doi:10.2217/crc.13.23
Mechanisms of KRAS-Mediated Pancreatic Tumor Formation and Progression: A Dissertation
Appleman, V. A. (2012) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/ekp2-9e89
The Clinical Significance of Mutations in Colorectal Cancer
Huang, F. W., Kleiman, L. B., & Hong, T. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8412-7_8
The Phosphatidylinositol 3‐Kinase Pathway in Human Malignancies
Klempner, S. J., Vo, T.-T. T., Myers, A. P., & Cantley, L. C. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch32
Self-citationArpalahti, L. (2018) · Helda - University of Helsinki Institutional Repository
Investigations into how best to target FGFR2 mutant endometrial cancer
Geng, X. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.123437
Regulation of the kRAS Promoter in Pancreatic Cancer by Proteins and Small Molecules
Batra, H. (2017) · ProQuest Demo Repository
G-Quadruplexes As Molecular Targets For Transcriptional Control
Morgan, R. K. (2017)
Rathore, M. G., Wright, M., Bhattacharya, R., Fan, F., Gohar, A. V., Winter, J. M., Wang, Z., Markowitz, S. D., Willis, J. E., Ellis, L. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.27.441690
Rathore, M. G., Wright, M., Bhattacharya, R., Fan, F., Gohar, A. V., Winter, J. M., Wang, Z., Markowitz, S. D., Willis, J. E., Ellis, L. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-745208/v1
Wang, Z., Kang, B., Gao, Q., Huang, L., Fan, Y., Yu, J., Di, J., Jiang, B., Gao, F., Wang, D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-230629/v1
Suppression of Breast Cancer Metastasis Through the Inactivation of ADP-Ribosylation Factor 1
Xie, X., Tang, S., Cai, Y., Pi, W., Deng, L., Wu, G., Chavanieu, A., & Teng, Y. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr.1.2020.16
Data from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., de la Cruz, F. F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2023) · doi:10.1158/1078-0432.c.6529850.v1
Self-citationData from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., de la Cruz, F. F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2023) · doi:10.1158/1078-0432.c.6529850
Self-citation
Metadata
- Authors
- Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., Wong, K.-K., Cantley, L. C., & Engelman, J. A.
- Affiliations
- Massachusetts General Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Engelman, Jeffrey A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-11-01
- Volume
- 121
- Issue
- 11
- Pages
- 4311-4321
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3204842
- OpenAlex
- W2030733555
- Cited by
- 210
- References
- 56
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 8 · 2021: 18 · 2020: 19 · 2019: 16 · 2018: 11 · 2017: 21 · 2016: 16 · 2015: 12 · 2014: 26 · 2013: 23 · 2012: 19
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- V Foundation for Cancer Research
- Uniting Against Lung Cancer
- Brigham and Women's Hospital
- Massachusetts General Hospital
- Kanae Foundation for the Promotion of Medical Science
- National Institutes of Health
- National Cancer Institute (P50CA127003, U01CA141457, RC2CA147940, R01CA122794, R01CA140594, CA127003, P50CA090578, K08CA120060, K99CA149169, CA120060-01, R01CA137181, R01CA137008)
- National Institute of General Medical Sciences (R01-GM41890, R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- receptor tyrosine kinase, PI3K/Akt signaling, MEK/ERK signaling, KRAS mutation, colorectal cancer, receptor tyrosine kinase inhibitors, IGF-1 receptor, combination therapy, MEK inhibitors, apoptosis, drug resistance, Akt phosphorylation
- MeSH terms
- Animals, Base Sequence, Humans, Male, Mice, Nude, Mutation, Neoplasm Transplantation, Proto-Oncogene Proteins, Transplantation, Heterologous, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Apoptosis, DNA Primers, ras Proteins, Phosphatidylinositol 3-Kinases, Receptor Protein-Tyrosine Kinases, MAP Kinase Signaling System, RNA, Small Interfering, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt, Mice, Gene Knockdown Techniques, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.